Abstract
Chemoresistance in cancer has previously been attributed to gene mutations or deficiencies. Bax or p53 deficiency can lead to resistance to cancer drugs. We aimed to find an agent to overcome chemoresistance induced by Bax or p53 deficiency. Here, we used immunoblot, flow-cytometry analysis, gene interference, etc. to show that genistein, a major component of isoflavone that is known to have anti-tumor activities in a variety of models, induces Bax/p53-independent cell death in HCT116 Bax knockout (KO), HCT116 p53 KO, DU145 Bax KO, or DU145 p53 KO cells that express wild-type (WT) Bak. Bak knockdown (KD) only partially attenuated genistein-induced apoptosis. Further results indicated that the release of AIF and endoG also contributes to genistein-induced cell death, which is independent of Bak activation. Conversely, AIF and endoG knockdown had little effect on Bak activation. Knockdown of either AIF or endoG alone could not efficiently inhibit apoptosis in cells treated with genistein, whereas an AIF, endoG, and Bak triple knockdown almost completely attenuated apoptosis. Next, we found that the Akt-Bid pathway mediates Bak-induced caspase-dependent and AIF- and endoG-induced caspase-independent cell death. Moreover, downstream caspase-3 could enhance the release of AIF and endoG as well as Bak activation via a positive feedback loop. Taken together, our data elaborate the detailed mechanisms of genistein in Bax/p53-independent apoptosis and indicate that caspase-3-enhanced Bid activation initiates the cell death pathway. Our results also suggest that genistein may be an effective agent for overcoming chemoresistance in cancers with dysfunctional Bax and p53.
Similar content being viewed by others
Main
Mammalian cell death proceeds through a highly regulated program called apoptosis that is highly dependent on the mitochondria.1 Mitochondrial outer membrane (MOM) multiple apoptotic stresses permeabilize the MOM, resulting in the release of apoptogenic factors including cytochrome c, Smac, AIF, and endoG.2, 3, 4 Released cytochrome c activates Apaf-1, which assists in caspase activation. Then, activated caspases cleave cellular proteins and contribute to the morphological and biochemical changes associated with apoptosis. Bcl-2 family proteins control a crucial apoptosis checkpoint in the mitochondria.2, 5, 6, 7 Multidomain proapoptotic Bax and Bak are essential effectors responsible for the permeabilization of the MOM, whereas anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 preserve mitochondrial integrity and prevent cytochrome c efflux triggered by apoptotic stimuli. The third Bcl-2 subfamily of proteins, BH3-only molecules (BH3s), promotes apoptosis by either activating Bax/Bak or inactivating Bcl-2/Bcl-xL/Mcl-1.8, 9, 10, 11, 12 Upon apoptosis, the ‘activator’ BH3s, including truncated Bid (tBid), Bim, and Puma, activate Bax and Bak to mediate cytochrome c efflux, leading to caspase activation.8, 11, 12 Conversely, antiapoptotic Bcl-2, Bcl-xL, and Mcl-1 sequester activator BH3s into inert complexes, which prevents Bax/Bak activation.8, 9 Although it has been proposed that Bax and Bak activation occurs by default as long as all of the anti-apoptotic Bcl-2 proteins are neutralized by BH3s,13 liposome studies clearly recapitulate the direct activation model in which tBid or BH3 domain peptides derived from Bid or Bim induce Bax or Bak oligomerization and membrane permeabilization.12, 14, 15
Numerous studies have demonstrated a critical role for Bax in determining tumor cell sensitivity to drug induction and in tumor development. Bax has been reported to be mutated in colon16, 17 and prostate cancers,18, 19 contributing to tumor cell survival and promoting clonal expansion. Bax has been shown to restrain tumorigenesis20 and is necessary for tBid-induced cancer cell apoptosis.21 Loss of Bax has been reported to promote tumor development in animal models.22 Bax knockout (KO) renders HCT116 cells resistant to a series of apoptosis inducers.23, 24, 25 p53 has been reported to be a tumor suppressor,26 and its mutant can cause chemoresistance in cancer cells.27, 28, 29 Moreover, p53 is often inactivated in solid tumors via deletions or point mutations.30, 31 Thus, it is necessary to find an efficient approach or agent to overcome chemoresistance caused by Bax and/or p53 mutants.
Few studies have focused on the role of Bak in tumor cell apoptosis and cancer development. Bak mutations have only been shown in gastric and colon cancer cells.32 Some studies have revealed that Bak is a determinant of cancer cell apoptosis.33, 34 Some studies have even demonstrated that Bak renders Bax KO cells sensitive to drug induction.33, 35 In this study, we are the first group to show that tBid induces Bak activation and the release of AIF and endoG in colon cancer cells, which causes cellular apoptosis independent of Bax/p53. We also found that caspase-3 is activated in apoptosis. Interestingly, downstream caspase-3 can strengthen Bak activation and the release of AIF and endoG during apoptosis via a feedback loop. Furthermore, we reveal that Akt upregulates apoptosis progression. These results will help us to better understand the function of mitochondrial apoptotic protein members in apoptosis and cancer therapies. Furthermore, our experiments may provide a theoretical basis for overcoming chemoresistance in cancer cells.
Results
Genistein induces Bax and p53-independent apoptosis in cancer cells
We first determined the apoptotic effects of genistein in HCT116 Bax KO and p53 KO cells. We treated the cells with genistein at the indicated time, and apoptosis was assessed by a DNA fragmentation ELISA. As depicted in Figure 1a, genistein efficiently induced cell death in HCT116 Bax KO, p53 KO, DU145 KO, and p53 KO cells. Flow-cytometry analysis with Annexin V/PI staining also revealed that genistein could induce apoptosis in these cell lines (Figure 1b). Moreover, our data demonstrated that genistein effectively induced Cyt c release from the mitochondria to the cytosol (Figure 1c). Next, we stably transfected p53 shRNAs into HCT116 Bax KO or DU145 Bax KO cells to make p53 knockdown cell lines (Figure 2a). Both flow-cytometry analysis (Figure 2b) and ELISA (Figure 2c) revealed that p53 knockdown had little effect on cell apoptosis by genistein. Meanwhile, we transiently transfected Bax siRNA (si Bax) into HCT116 p53 KO or DU145 p53 KO cells to make Bax knockdown cell lines (Supplementary Figure 1A). Flow-cytometry analysis demonstrated that Bax deficiency also had little effect on cell death in p53 KO cells (Figure 2d). These results indicate that genistein caused apoptosis independent of Bax and p53.
Bak activation is important for genistein-induced apoptosis
Because Bak contributes to Bax-independent cell death,33, 36 we speculated that Bak could mediate genistein-induced Bax/p53-independent cell death. Our experiments revealed that genistein induced Bak oligomerization and a conformational change in p53 or Bax KO cells (Figure 3a). Meanwhile, we still detected Bak oligomerization in Bax KD/p53 KO or Bax KO/p53 KD cells. Genistein treatment was still sufficient to induce Bak oligomerization in Bax KD/p53 KO or Bax KO/p53 KD cancer cells (Supplementary Figure 1B).
To further investigate the contribution of Bak to cell apoptosis, we transfected Bak siRNAs (si Bak) into HCT116 Bax KO or p53 KO cells to knock down Bak expression. Western blot analysis confirmed the lack of Bak expression in cancer cells (Figure 3b). As illustrated in Figures 3b and c, Bak siRNAs efficiently decreased Cyt c release and caspase-3 activation. Meanwhile, Bak knockdown also decreased cell death in cancer cells treated with genistein (Figure 3f). Further experiments revealed that Bcl-2 overexpression obviously inhibited Bak oligomerization and the conformational change as well as apoptosis by genistein (Figures 3d, e, and g). These results suggest that Bak has an important role in genistein-induced Bax/p53-independent cell apoptosis.
The release of AIF and endoG from the mitochondria to the cytosol mediates apoptosis
Our experiments also found that genistein induced the release of AIF and endoG in Bax or p53 KO cancer cells (Figure 4a). AIF and endoG are important factors for mitochondrial apoptosis and can mediate caspase-dependent and -independent cell death.3, 37 We then used AIF siRNAs (si AIF), endoG siRNAs (si endoG), or both siRNAs (si AIF/endoG) to decrease AIF and endoG expression in cancer cells (Figures 4b and c). We found that knockdown of either AIF or endoG alone could not efficiently decrease apoptosis in cells treated with genistein. However, the AIF and endoG double knockdown substantially decreased apoptosis (Figures 4d and e). These results indicate that the release of mitochondrial AIF and endoG is necessary for genistein-induced Bax/p53-independent cell apoptosis.
Bid causes Bak activation and the release of AIF and endoG during apoptosis
Our study revealed that Bak could induce the release of Cyt c from the mitochondria to the cytosol; thus, we detected whether Bak induced the release of AIF and endoG during apoptosis. We knocked down the expression of Bak with siRNAs in cancer cells. We found that Bak knockdown had little effect on the release of AIF and endoG (Figure 5a). Similarly, AIF and endoG knockdown had little effect on Bak activation (Figure 5b). These results indicate that Bak activation and the release of AIF and endoG are likely parallel apoptotic events. Indeed, we found that a Bak, AIF, and endoG triple knockdown almost completely inhibited apoptosis in cells treated with genistein (Figure 5c). We speculated that the other factors can cause Bak activation as well as the release of AIF and endoG during apoptosis.
Previous studies have demonstrated that activated Bid can mediate Bak activation and the release of AIF and endoG.38, 39, 40 We then detected whether Bid contributes to genistein-induced cell apoptosis. We first detected Bid expression and activation. Our data confirmed that Bid was cleaved into tBid (Figure 6a), which is the active truncated form of Bid,38 during the time course of genistein treatment. We also found that tBid translocated into the mitochondria from the cytosol (Figure 6b), which could induce the release of mitochondrial proteins.41 We then knocked down the expression of Bid with siRNAs. Our data revealed that Bid expression was inhibited by siRNA treatment (Figure 6c). Moreover, Bid knockdown affected Bak oligomerization; the release of Cyt c, AIF, and endoG; and caspase-3 cleavage in Bax or p53 KO cells (Figure 6c). Meanwhile, Bid knockdown also substantially decreased apoptosis in Bax or p53 KO cells treated with genistein (Figure 6d). We also transiently transfected Bid siRNAs into Bax KD/p53 KO or Bax KO/p53 KD cells. We found that Bid knockdown is sufficient to attenuate Bak oligomerization; the release of Cyt c, AIF, and endoG; and caspase-3 cleavage in cancer cells (Supplementary Figures 1C and D). These results demonstrated that Bid could upregulate Bak activation; the release of AIF and endoG; and subsequently apoptosis.
Akt inactivation mediates Bid-induced cell apoptosis
Previous studies have revealed that Akt activation could inhibit tBid appearance and Bid-induced apoptosis.42, 43 Moreover, a previous study showed that genistein induced apoptosis through the Akt pathway in anaplastic large-cell lymphoma.44 Thus, we speculated that Akt is the upstream apoptotic regulator in our experiments. We first detected phosphorylated Akt (p-Akt) and total Akt (t-Akt) expression. We found that p-Akt was decreased during the time course of genistein treatment. Meanwhile, t-Akt had little change after treatment (Figure 7a). We then further detected the effects of Akt on apoptosis. We transfected a constitutively active Akt1 construct into cancer cells and found that Akt1 overexpression increased t-Akt in cells (Figure 7b). Moreover, Akt1 overexpression obviously inhibited the appearance of tBid, Bak oligomerization, caspase-3 cleavage, and the release of AIF and endoG (Figure 7c). Our experiments also revealed that LY294002, a PI3K/Akt pathway inhibitor that inactivates Akt, efficiently increased Bid activation, Bak oligomerization, caspase-3 cleavage, and the release of AIF and endoG (Figure 7c). These results indicate that Akt inactivation mediates Bid-induced downstream apoptotic events instigated by genistein.
Caspase-3 enhances Bid-induced Bak activation and the release of AIF and endoG
Previous reports have revealed that downstream apoptotic factors, such as Smac and caspase-9, could mediate upstream apoptotic events through positive feedback.2, 5, 45 Thus, we detected whether caspase-3 could enhance Bak activation. We first knocked down caspase-3 with siRNAs (si Cas-3). We found that caspase-3 expression was inhibited by siRNAs in cancer cells (Figure 8a). Our data indeed revealed that caspase-3 knockdown decreased Cyt c release and Bak oligomerization (Figure 8b). However, interestingly, caspase-3 knockdown also obviously decreased the release of AIF and endoG (Figure 8b). Moreover, caspase-3 knockdown had little effect on Bid activation (Figure 8c). These results suggest that downstream caspase-3 could enhance Bid-induced subsequent apoptotic events, but did not affect Bid activation.
To further examine the effect of caspase-3 during apoptosis, we transfected an XIAP construct into cancer cells to antagonize caspase-3 activation. The cleavage of caspase-3 could be blocked by XIAP overexpression. XIAP overexpression could also decrease apoptosis.46 Our data revealed that the XIAP construct increased XIAP overexpression and decreased apoptosis in cells treated with genistein (Figure 8d). XIAP overexpression inhibited caspase-3 cleavage, Bak oligomerization, and the release of Cyt c. XIAP overexpression also decreased the release of AIF and endoG from the mitochondria (Figure 8e). These results further revealed that downstream caspase-3 could enhance Bid-induced apoptosis.
Discussion
Genistein, a naturally occurring isoflavone and prominent isoflavonoid found in soy products, is of interest because of its potent chemotherapeutic activities, including its ability to inhibit cell growth and induce apoptosis in a wide variety of cultured cancer cells.44, 47, 48, 49, 50, 51 Moreover, genistein has chemopreventive effects in several human malignancies, including cancers of the breast, colon, and prostate.49, 52 Previous studies have revealed that genistein induces apoptosis in breast cancer cells by upregulating pro-apoptotic Bcl-2 proteins, such as Bax or Bak, and downregulating anti-apoptotic factors, such as Bcl-xL or Bcl-2.48, 53 Some studies have also revealed that genistein involves the Akt signaling pathway in apoptosis.44, 47 However, the exact function of genistein on cancer chemoresistance is still unknown.
In the present study, we first demonstrated that genistein can induce apoptosis independent of Bax and p53. Previous studies have demonstrated that genistein induced apoptosis independent of p53.53 We focused on genistein and found out that genistein can induce cell death in the absence of Bax and p53. We found that Bak compensates for the loss of Bax in cancer cell apoptosis. However, Bak knockdown only partially inhibited apoptosis in cells treated with genistein. These results suggest that Bak may not be the sole decisive factor for genistein-induced apoptosis.
Mitochondria respond to multiple death stimuli including those involving pro-apoptotic Bcl-2 family proteins, such as Bax and Bak, which induce mitochondrial membrane permeabilization and cause the release of apoptotic molecules.2, 6, 33, 38 Therefore, we speculated that Bak could mediate the release of some mitochondrial apoptotic factors, such as Cyt c, AIF, and endoG. Indeed, our data revealed that the release of AIF and endoG from that mitochondria was an important part of genistein-induced cell death. It has been reported that AIF and endoG translocate to the nucleus to trigger caspase-independent cell death.37 Our data also revealed that Bak mediated the release of Cyt c. Bak knockdown efficiently inhibited the release of Cyt c. However, interestingly, Bak knockdown had little effect on the release of AIF and endoG. Conversely, an AIF and endoG double knockdown did not affect Bak activation. These results lead us to believe that another upstream factor mediates genistein-induced apoptosis.
Previous studies have also revealed that the Akt signaling pathway contributes to genistein-induced apoptosis44, 47 Our data further demonstrated that the Akt-Bid signaling pathway upregulates Bak activation and the release of AIF and endoG. Further experiments revealed that downstream caspase-3 could enhance Bak activation and the release of AIF and endoG. Arnoult et al.3 revealed that mitochondrial 'release of AIF and endoG required caspase activation. Our study also confirmed this conclusion. Moreover, we also proved that Bak did not contribute to the release of AIF and endoG. Arnoult et al. also found that tBid could induce the release of Cyt c, but not AIF and endoG. However, our research revealed that tBid could induce the release of Cyt c, AIF, and endoG, as described previously.39, 54 Furthermore, we also found that caspase-3 inhibition decreased the release of mitochondrial apoptotic factors, whereas previous studies have shown that caspase inhibitors prevent the mitochondrial release of AIF and endoG, but not Cyt c. This result further suggests that we have found a different mechanism underlying the regulation of Bak activation and the release of AIF and endoG.
In conclusion, we explored, for the first time, the detailed molecular mechanisms of Bid-induced apoptosis after genistein treatment and demonstrate that caspase-3 could enhance genistein-induced apoptosis. Our findings explain how genistein induces apoptosis in Bax- and p53-deficient cancer cells. The Akt-Bid pathway initiates Bak activation and downstream caspase processing. Meanwhile, the Akt-Bid pathway also causes the release of AIF and endoG, which induces caspase-independent cell death. Downstream caspase-3 reinforces Bak activation and the release of AIF and endoG through positive amplification loops (Figure 9). These positive regulatory feedback loops sensitize cancer cells to treatment with genistein. Genistein seems to have broader implications, even in a clinical perspective.
Materials and Methods
Materials
Genistein, LY294002, Annexin V, and PI were obtained from Sigma (St. Louis, MO, USA). Bak (B5897) and actin (clone AC-74, A5316) antibodies were also from Sigma. Bismaleimidohexane (BMH) was obtained from Pierce (Rockford, IL, USA). Prestained marker (SM0671) was from Fermentas (Vilnius, Lithuania). Bak (Ab-2) was purchased from Calbiochem (San Diego, CA, USA). p53 (clone 7F5, #2527), phospho-Akt (Ser 473) (clone 587F11, #4051), Akt (#9272), caspase-3 (clone 8G10, #9665), Bid (#2002), XIAP (#2042), AIF (#4642), and Cox IV (#4844) were purchased from Cell Signaling (Beverly, MA, USA). EndoG (ab9647) antibody was from Abcam (Cambridge, UK). Cyt c (sc-13156), Bcl-2 (sc-7382), and Bax N-20 (sc-493) antibodies were from Santa Cruz (Santa Cruz, CA, USA).
Gene silencing with small interfering rnas and plasmids
Small interfering RNA (siRNA) oligonucleotides were purchased from Dharmacon (Lafayette, CO, USA) with sequences targeting Bax (5′-AACUGAUCAGAACCAUCAUGG-3′), Bak (5′-AACCGACGCUAUGACUCAGAG-3′), Bid (5′-AAGAAGACAUCAUCCGGAAUA-3′) AIF (5′-GGCUACGUCCAGGAGCGCACC-3′), endoG (5′-AAGAGCCGCGAGUCGUACGUG-3′), caspase-3 (5′-UGAGGUAGCUUCAUAGUGGTT-3′), and p53 (5′-CGGCAUGAACCGGAGGCCCAU-3′). For p53 shRNA construction, the siRNA was cloned into the pSilencer 2.1-U6 hygro plasmid. The constitutively active Akt1 construct HA-PKB-T308D/S473D was obtained as previously described.5, 55
Cell culture and transfection
DU145 and HCT116 cells were obtained from the American Type Culture Collection. DU145 and HCT116 cells were incubated in DMEM supplemented with 10% FBS and penicillin-streptomycin. HCT116 Bax KO6 cells were the gift from Quan Chen (Chinese Academy of Sciences, Beijing, China). DU145 Bax KO, DU 145 p53 KO, and HCT116 p53 KO were obtained from Dean G. Tang (the University of Texas MD Anderson Cancer Center, Science Park-Research Division, Smithville, TX, USA).
For siRNA or shRNA transfection, cells were seeded on 6-well plates and then transfected with the appropriate plasmid DNA or siRNA using the manufacturers’ protocols. Typically, cells were seeded on coverslips in the 6-well plates, and then 1 μg of plasmid DNA or 100 nM siRNA and 4 μl of DMRIE-C reagent (Invitrogen, Carlsbad, CA, USA) were used per coverslip. The cells were incubated for 4 h in the transfection mixture, which was then replaced with fresh culture medium. For stable transfection, cells were transfected with the constructs as previously described.2, 6 Positive clones were selected with 600 μg/ml hygromycin (Invitrogen) for several weeks.
Apoptosis assays
Three methods were used to assess PL-induced apoptotic cell death: detection of DNA fragmentation with the Cell Death Detection ELISA kit (Roche Diagnostics, Castle Hill, NSW, Australia), Western blot analysis of caspase-3 cleavage, Cyt c, AIF, or endoG release and measurement of apoptotic cells by flow cytometry (Annexin/PI, Bak activation, or activated caspase-3). The Cell Death Detection ELISA quantified the apoptotic cells by detecting the histone-associated DNA fragments (mono- and oligo-nucleosomes) generated by the apoptotic cells.5
Cell fractionation and western blot analysis
Mitochondria and cytoplasm from cells were fractionated by differential centrifugation as previously described.5 Cytosol, mitochondria, total lysates, and immunoprecipitates were analyzed by western blot with antibody dilutions as follows: actin at 1:20 000; AIF, caspase-3, endoG, p53, Akt, p-Akt, Bid, XIAP, CoxIV at 1:2000; and Bax, Bak, Cyt c at 1:1000.
Bak oligomerization and bak conformational change
Cells were treated with agents and incubated with 1 mM BMH in 10% DMSO or DMSO alone for 30 min at 25 °C. After centrifugation at 5000 × g for 25 min at 4 °C, the reaction was split into supernatant and pellet fractions. The pelleted material (10 mg total protein) was separated by SDS-PAGE and immunoblotted with anti-Bak antibody to detect Bak oligomerization.56 Bak conformational change was performed as described.57 Briefly, cells were lysed in 1% CHAPS buffer, and 250 μg of protein was immunoprecipitated using anti-Bak (Ab-2), which only recognizes Bak that has undergone a conformation change. Immunoprecipitated protein was then subjected to immunoblot analysis by using anti-Bak as primary antibodies.
Statistical analysis
Statistical analysis of the differences between the groups was performed using the Student's t-test with P<0.05 considered as statistically significant.
Abbreviations
- AIF:
-
apoptosis-inducing factor
- BMH:
-
Bismaleimidohexane
- Cyt c:
-
cytochrome c
- endoG:
-
endonuclease G
- KO:
-
knockout
- KD:
-
knockdown
- p-Akt:
-
Akt phosphorylation
- MOM:
-
mitochondrial outer membrane
- WD:
-
wild type
References
Danial NN, Korsmeyer SJ . Cell death: critical control points. Cell 2004; 116: 205–219.
Hu W, Wang F, Tang J, Liu X, Yuan Z, Nie C et al. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101. J Biol Chem 2012; 287: 68–80.
Arnoult D, Gaume B, Karbowski M, Sharpe JC, Cecconi F, Youle RJ . Mitochondrial release of AIF and EndoG requires caspase activation downstream of Bax/Bak-mediated permeabilization. EMBO J 2003; 22: 4385–4399.
Wang X . The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922–2933.
Nie C, Luo Y, Zhao X, Luo N, Tong A, Liu X et al. Caspase-9 mediates Puma activation in UCN-01-induced apoptosis. Cell Death Dis 2014; 5: e1495.
Nie C, Tian C, Zhao L, Petit PX, Mehrpour M, Chen Q . Cysteine 62 of Bax is critical for its conformational activation and its proapoptotic activity in response to H2O2-induced apoptosis. J Biol Chem 2008; 283: 15359–15369.
Cory S, Adams JM . The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–656.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8: 705–711.
Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ et al. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 1348–1358.
Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525–535.
Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP et al. Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol Cell 2009; 36: 487–499.
Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH . Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166–1173.
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856–859.
Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331–342.
Walensky LD . BCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13: 1339–1350.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275: 967–969.
Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M . Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA 2000; 97: 10872–10877.
Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996; 148: 1567–1576.
Tang DG, Li L, Chopra DP, Porter AT . Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 1998; 58: 3466–3479.
Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T . Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 1997; 385: 637–640.
Desagher S, Osen-Sand A, Nichols A, Eskes R, Montessuit S, Lauper S et al. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 1999; 144: 891–901.
Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999; 18: 2692–2701.
Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B . Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290: 989–992.
Theodorakis P, Lomonosova E, Chinnadurai G . Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res 2002; 62: 3373–3376.
He Q, Montalbano J, Corcoran C, Jin W, Huang Y, Sheikh MS . Effect of Bax deficiency on death receptor 5 and mitochondrial pathways during endoplasmic reticulum calcium pool depletion-induced apoptosis. Oncogene 2003; 22: 2674–2679.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447: 1130–1134.
Yang X, Fraser M, Moll UM, Basak A, Tsang BK . Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006; 66: 3126–3136.
Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK . p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003; 63: 7081–7088.
Fraser M, Bai T, Tsang BK . Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008; 122: 534–546.
Harris CC, Hollstein M . Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318–1327.
Levine AJ, Momand J, Finlay CA . The p53 tumour suppressor gene. Nature 1991; 351: 453–456.
Kondo S, Shinomura Y, Miyazaki Y, Kiyohara T, Tsutsui S, Kitamura S et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328–4330.
Hemmati PG, Guner D, Gillissen B, Wendt J, von Haefen C, Chinnadurai G et al. Bak functionally complements for loss of Bax during p14ARF-induced mitochondrial apoptosis in human cancer cells. Oncogene 2006; 25: 6582–6594.
Nieminen AI, Eskelinen VM, Haikala HM, Tervonen TA, Yan Y, Partanen JI et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci USA 2013; 110: E1839–E1848.
Gillissen B, Wendt J, Richter A, Muer A, Overkamp T, Gebhardt N et al. Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma. J Cell Biol 2010; 188: 851–862.
Wang J, Guo W, Zhou H, Luo N, Nie C, Zhao X et al. Mitochondrial p53 phosphorylation induces Bak-mediated and caspase-independent cell death. Oncotarget 2015; 6: 17192–17205.
Cregan SP, Dawson VL, Slack RS . Role of AIF in caspase-dependent and caspase-independent cell death. Oncogene 2004; 23: 2785–2796.
Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M et al. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060–2071.
Miyake K, Bekisz J, Zhao T, Clark CR, Zoon KC . Apoptosis-inducing factor (AIF) is targeted in IFN-alpha2a-induced Bid-mediated apoptosis through Bak activation in ovarian cancer cells. Biochim Biophys Acta 2012; 1823: 1378–1388.
Landshamer S, Hoehn M, Barth N, Duvezin-Caubet S, Schwake G, Tobaben S et al. Bid-induced release of AIF from mitochondria causes immediate neuronal cell death. Cell Death Differ 2008; 15: 1553–1563.
Shiozaki EN, Shi Y . Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 2004; 29: 486–494.
Majewski N, Nogueira V, Robey RB, Hay N . Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 2004; 24: 730–740.
Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piche A . The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 2010; 29: 5523–5536.
Park SS, Kim YN, Jeon YK, Kim YA, Kim JE, Kim H et al. Genistein-induced apoptosis via Akt signaling pathway in anaplastic large-cell lymphoma. Cancer Chemother Pharmacol 2005; 56: 271–278.
Yu J, Wang P, Ming L, Wood MA, Zhang L . SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 2007; 26: 4189–4198.
Asselin E, Mills GB, Tsang BK . XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001; 61: 1862–1868.
Nakamura Y, Yogosawa S, Izutani Y, Watanabe H, Otsuji E, Sakai T . A combination of indol-3-carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting Akt phosphorylation and progression of autophagy. Mol Cancer 2009; 8: 100.
Po LS, Wang TT, Chen ZY, Leung LK . Genistein-induced apoptosis in MCF-7 cells involves changes in Bak and Bcl-x without evidence of anti-oestrogenic effects. Br J Nutr 2002; 88: 463–469.
Li M, Zhang Z, Hill DL, Chen X, Wang H, Genistein Zhang R . a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptional and posttranslational levels. Cancer Res 2005; 65: 8200–8208.
Chiyomaru T, Yamamura S, Fukuhara S, Yoshino H, Kinoshita T, Majid S et al. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR. PLoS One 2013; 8: e70372.
Pavese JM, Krishna SN, Bergan RC . Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis. Am J Clin Nutr 2014; 100: 431S–436S.
Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, Helenowski I et al. Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Res 2008; 68: 2024–2032.
Li Y, Upadhyay S, Bhuiyan M, Sarkar FH . Induction of apoptosis in breast cancer cells MDA-MB-231 by genistein. Oncogene 1999; 18: 3166–3172.
Zhao T, Zhang H, Guo Y, Fan Z . Granzyme K directly processes bid to release cytochrome c and endonuclease G leading to mitochondria-dependent cell death. J Biol Chem 2007; 282: 12104–12111.
Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL . Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 2008; 68: 6698–6707.
Chandra D, Choy G, Daniel PT, Tang DG . Bax-dependent regulation of Bak by voltage-dependent anion channel 2. J Biol Chem 2005; 280: 19051–19061.
Chen S, Dai Y, Pei XY, Grant S . Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 2009; 29: 6149–6169.
Acknowledgements
This work was supported by Natural Science Foundation of China (NSFC)-81272458, Program for New Century Excellent Talents in University (NCET)-12-0381, and Sichuan Province Science and technology support program-2014SZ0045.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Edited by S Lavandero
Supplementary Information accompanies this paper on Cell Death and Disease website
Supplementary information
Rights and permissions
Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Guo, W., Zhang, Y., Ling, Z. et al. Caspase-3 feedback loop enhances Bid-induced AIF/endoG and Bak activation in Bax and p53-independent manner. Cell Death Dis 6, e1919 (2015). https://doi.org/10.1038/cddis.2015.276
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2015.276
- Springer Nature Limited
This article is cited by
-
Cytoplasmic Endonuclease G promotes nonalcoholic fatty liver disease via mTORC2-AKT-ACLY and endoplasmic reticulum stress
Nature Communications (2023)
-
Drastic Loss of Antral Follicles Due to Gene Expression Dysregulation Occurs on the First Day After Subcutaneous Ovarian Transplantation
Reproductive Sciences (2023)
-
Endonuclease G promotes autophagy by suppressing mTOR signaling and activating the DNA damage response
Nature Communications (2021)
-
ARD1 contributes to IKKβ-mediated breast cancer tumorigenesis
Cell Death & Disease (2018)
-
Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death
British Journal of Cancer (2017)